Clinical Trials › NCT06451159
Active, Not RecruitingPhase 1
A Study of KYV-101, a CD19 CAR T Cell Therapy, in Participants With Treatment Refractory Progressive Multiple Sclerosis
Sponsored by Bruce Cree
Interested in joining? Eligibility criteria and contact info are on ClinicalTrials.gov.
View on ClinicalTrials.gov 10
Target enrollment
1
U.S. states
Jun 2024
Start date
Feb 2027
Expected completion
Interventions / Treatments
KYV-101 (Biological) - 0.33 ×10^8 cellsKYV-101 (Biological) - 1 ×10^8 cellsChemotherapy: cyclophosphamide (CYC)Chemotherapy: fludarabine (FLU)
Conditions studied
Progressive Multiple Sclerosis
Where this trial is running (1 site)
California1 site
San Francisco
Participating MS centers on MS Buddy (1)
UCSF Multiple Sclerosis Center
San Francisco, CA
San Francisco, CA
MS centers in California
Compare treatment centers near a trial site — patient experience, providers, and care ratings.
View California centersMore Phase 1 trials
Browse all Phase 1 MS trialsCheck out the MS Buddy App
Track symptoms, monitor wellness, and stay on top of your MS care. It's free, no ads. How? It's made and supported by MS patients who get their ideas from other MS patients.
